Case 1:
Conflict of Interest and Disclosure

Dr. M is a cancer researcher and is submitting a grant application seeking support for a randomized clinical trial evaluating the safety and efficacy of Newblockbusteron, a drug manufactured by Newbigpharma Inc., compared to Oldblockbusteron, a drug which is the current standard of care and is manufactured by Oldbigpharma Inc.

For each of the questions below, answer “yes” or “no” with regard to whether the financial interest must be disclosed and reviewed under the policy for your primary institution. Also consider whether or not the investigator should be prohibited from conducting the research in any of the scenarios.

1. Dr. M. gives after-dinner talks on cancer research for Newbigpharma that are completely unrelated to either Newblockbusteron or Oldblockbusteron, for which he receives $15,000 annually.
2. Same as question 1, except that the annual income is $2,000.
3. Same as question 1, except that the talks are for Oldbigpharma.
4. Dr. M is also engaged in outside consulting for Anotherbigpharma, Inc. which pays him over $10,000 per year to provide strategic advice on promising directions in the field of arthritis therapy, which are unrelated to the Newblockbusteron clinical trial.
5. Dr. M's wife owns $1,000 worth of stock in Oldbigpharma.
6. Dr. M's brother-in-law is an employee of Newbigpharma.
7. Dr. M is a co-inventor of Newblockbusteron and receives annual distributions of royalty payments for the inventions through the university.
8. The Chair of Dr. M's department has indicated that if the grant application is awarded and he publishes the results of the study, he will be promoted to full professor, receive a 20% salary increase, and be given a share of indirect costs from the study that will go into a discretionary account that Dr. M can use for professional and other university business purposes.
9. Part of the grant funds will be used to pay for Dr. M to travel to Newbigpharma headquarters located in the Great Caymans to review certain aspects of the clinical trial.
10. Same question as 9, except Newbigpharma agrees to reimburse the University for Dr. M's travel costs.
Case 1 Answers: Conflict of Interest and Disclosure

Disclosure requirements for policies in effect at University of Washington, Seattle WA (UW) and Fred Hutchinson Cancer Research Center (FHCRC).

<table>
<thead>
<tr>
<th>Institution</th>
<th>Yes</th>
<th>No</th>
<th>Not Covered By Institutional Conflict of Interest Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>UW</td>
<td>1,2,3,5,7</td>
<td>4,6,8,9,10</td>
<td>N/A</td>
</tr>
<tr>
<td>FHCRC</td>
<td>1, 2, 3, 4, 5, 7, 10 (see note below)</td>
<td>6</td>
<td>8, 9</td>
</tr>
</tbody>
</table>

Note: FHCRC researchers, as well as their spouses, domestic partners, and dependent children, must disclose for review any interest in, payments from, or relationship with for-profit companies that are engaged in business that might relate to research at FHCRC.